This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Esperion Therapeutics stock | $30.08

Own Esperion Therapeutics stock in just a few minutes.

Posted

Fact checked

Esperion Therapeutics, Inc is a biotechnology business based in the US. Esperion Therapeutics shares (ESPR) are listed on the NASDAQ and all prices are listed in US Dollars. Esperion Therapeutics employs 193 staff and has a trailing 12-month revenue of around USD$216 million.

How to buy shares in Esperion Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Esperion Therapeutics. Find the stock by name or ticker symbol: ESPR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Esperion Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$30.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Esperion Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Esperion Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Esperion Therapeutics share price

Use our graph to track the performance of ESPR stocks over time.

Esperion Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$30.08
52-week range USD$24.82 - USD$76.98
50-day moving average USD$36.2253
200-day moving average USD$40.2313
Wall St. target price USD$82.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.863

Buy Esperion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Esperion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Esperion Therapeutics price performance over time

Historical closes compared with the close of $30.08 from 2020-11-16

1 week (2020-11-25) 11.49%
1 month (2020-11-06) 19.13%
3 months (2020-09-04) -20.84%
6 months (2020-06-05) -33.67%
1 year (2019-12-05) -36.00%
2 years (2018-12-04) -43.79%
3 years (2017-12-05) -48.71%
5 years (2015-12-04) 8.16%

Esperion Therapeutics financials

Revenue TTM USD$216 million
Gross profit TTM USD$-27,247,000
Return on assets TTM -13.69%
Return on equity TTM -78.17%
Profit margin -38.86%
Book value $3.08
Market capitalisation USD$944.7 million

TTM: trailing 12 months

Shorting Esperion Therapeutics shares

There are currently 11.1 million Esperion Therapeutics shares held short by investors – that's known as Esperion Therapeutics's "short interest". This figure is 0.3% down from 11.2 million last month.

There are a few different ways that this level of interest in shorting Esperion Therapeutics shares can be evaluated.

Esperion Therapeutics's "short interest ratio" (SIR)

Esperion Therapeutics's "short interest ratio" (SIR) is the quantity of Esperion Therapeutics shares currently shorted divided by the average quantity of Esperion Therapeutics shares traded daily (recently around 500390.47619048). Esperion Therapeutics's SIR currently stands at 22.26. In other words for every 100,000 Esperion Therapeutics shares traded daily on the market, roughly 22260 shares are currently held short.

However Esperion Therapeutics's short interest can also be evaluated against the total number of Esperion Therapeutics shares, or, against the total number of tradable Esperion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Esperion Therapeutics's short interest could be expressed as 0.4% of the outstanding shares (for every 100,000 Esperion Therapeutics shares in existence, roughly 400 shares are currently held short) or 0.4657% of the tradable shares (for every 100,000 tradable Esperion Therapeutics shares, roughly 466 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Esperion Therapeutics.

Find out more about how you can short Esperion Therapeutics stock.

Esperion Therapeutics share dividends

We're not expecting Esperion Therapeutics to pay a dividend over the next 12 months.

Have Esperion Therapeutics's shares ever split?

Esperion Therapeutics's shares were split on a 1:6 basis on 11 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Esperion Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Esperion Therapeutics shares which in turn could have impacted Esperion Therapeutics's share price.

Esperion Therapeutics share price volatility

Over the last 12 months, Esperion Therapeutics's shares have ranged in value from as little as $24.82 up to $76.98. A popular way to gauge a stock's volatility is its "beta".

ESPR.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Esperion Therapeutics's is 1.6018. This would suggest that Esperion Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Esperion Therapeutics overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site